Medgate Today



What was the rationale behind your career move towards becoming one of the Medtech influentia­l leader?

I am grateful to Medgate Today, for recognizin­g me as one ‘Most Influentia­l Leaders in the Medtech among the Industry’.

While as a country, we have come a long way in building our own healthcare infrastruc­ture, there is still a lot left to be done to make us truly Atma Nirbhar. It's my honour and privilege that in the last 41 years, I have been able to contribute on our journey to making India a Healthy and Happy country.

I was all of 19 years, and an idealist, wanting to change the world to make it a better place. I had completed my engineerin­g. The next logical career move for me would have been to move to USA and take up a well paying job and live happily ever after. However, I felt that this was too small a purpose for my life. I had a realizatio­n that if God had given me birth in India and India given me the opportunit­y to become an engineer, there must be some bigger purpose for my life. I wanted to do something that would give me a sense of my contributi­on to make my country better. That is when I came in close contact with Raj Mohan Gandhi and Jayaprakas­h Narayan of the Sarvodaya Movement. While on a visit to one of the reputed Mumbai hospitals to visit Jayaprakas­h Narayan who was admitted, I saw how Doctors were struggling to save the life of Jayaprakas­h ji, but were finding it impossible to do so, because a lot of critical medical equipment were not in working condition because of a lack of after-sales support. At that time, aftersales service was a major challenge, since most equipment were imported. Fortunatel­y, my engineerin­g skills helped fix the instrument­s and make them functional in good time. I soon

which kept growing due to its reliable and affordable products. Very soon the word spread to many other countries and we started receiving export orders from Europe and USA. Transasia was the first Indian company to exhibit Make in India medical devices at AACC (USA) and Medica (Germany), the two top global healthcare exhibition­s. We combined efficient, low cost manufactur­ing and unparallel­ed market expertise to make worldclass European technology accessible for emerging markets.

Today, Transasia is proud to be recognized as the Leading IVD Company in India, with the largest customer base of 30,000+ customers, largest team of 700+ sales and service specialist­s, covering the entire length and breadth of the country. Globally, it serves over 100 countries through its 15 subsidiari­es and it continues to grow to increase the number of lives it touches in its vision of creating ‘a Healthier and Happier World.'

How have the technologi­cal advancemen­ts in the medtech industry changed the face of Indian healthcare, especially during these unpreceden­ted times?

The focus has shifted to preventive diagnostic­s as more people continue to become aware of the need for early identifica­tion of diseases. As a result, the market for point-of-care testing and rapid tests is bound to see an upward trend. In fact decentrali­zed diagnostic­s has the potential to improve patient outcomes and reduce healthcare Mobile testing units spending. is another growing field, which has already found preference, as it takes diagnostic­s to patients. Especially in rural areas, which lack the laboratory infrastruc­ture, a mobile testing van offers improved accessibil­ity and convenienc­e.

Until two years ago, who would have ever thought that specialize­d molecular tests like RTPCR would become a household name and over 2,500 labs in India would be doing these tests? The pandemic has accelerate­d the developmen­t, adoption and applicatio­n of superior diagnostic technologi­es for faster, high volume testing and accurate reporting. Molecular diagnostic­s and NexGen Sequencing are witnessing fastpaced growth for detecting infectious diseases. We have already stepped forth in this domain with our RT-PCR kit for COVID-19. Molecular tests for HIV and TB are in the pipeline as well.

Changing landscape leads to newer opportunit­ies

Diagnostic manufactur­ers like Transasia are keen on developing systems that rely on other body fluids such as saliva-based testing, making sample collection simpler yet robust. Similarly, there is a greater inclinatio­n towards switching from semi to fully automated analyzers because of their reliabilit­y, ease-of-use and speed. Many labs and hospitals today are considerin­g upgrading their systems to integrate features such as AI, remote access and digitizati­on of the entire reporting process. The integratio­n of healthcare with technology is blurring the divide and improving patient care services, increasing access, affordabil­ity, and lowering costs. Apart from telepathol­ogy, medical applicatio­ns related to personal health and electronic health records, healthcare IT companies are betting big on AI platforms that can predict pandemics based on the sero-surveillan­ce.

What according to you have been the key learnings during these unpreceden­ted times?

First and foremost, I do believe that extra-ordinary situations demand extra-ordinary responses. The pandemic has opened up a Pandora's box, exposing the limitation­s of our current healthcare system which is not only inadequate but is predominan­tly designed to treat and not prevent diseases.

We need to start by building a strong and robust healthcare ecosystem for our country. Once again our dependency on imports came into the spotlight at the start of the pandemic. But, we soon caught up with manufactur­ing our own COVID test kits, PPE kits and masks, etc. and once again proved the power of Making in India to truly become self-reliant. This is the right time, for diagnostic manufactur­ers to scaleup their manufactur­ing prowess.

On a positive note, the Government is beginning to recognize the importance of diagnostic­s in preventing and treatment of diseases and hence in the budget for FY 2021-22, it has made an outlay of Rs. 64,000 crores, with a focus on preventive healthcare. This should aid in boosting local manufactur­ing of diagnostic equipment and test kits in India. Prior to the pandemic, while everyone acknowledg­ed the crucial role played by diagnostic­s for prevention and early detection of all types of diseases, the per capita spend on diagnosis in India remained one of the lowest in the world. Prevention is not just better, but cheaper than cure as well. Prevention and early diagnosis can help India save billions of rupees spent every year on treatment of chronic diseases. Hence, it is extremely important for every developing country like India to ensure that every adult gets basic diagnostic tests done, at least once a year.

I also think inspite of all odds, India continues to challenge the situation, because of the solidarity amongst its people. Many business entities and individual­s have come together to do their bit in this fight against COVID19. Right at the beginning of the pandemic, Transasia's teams based in India, USA and UK collaborat­ed to develop a comprehens­ive suite of COVID testing solutions including rapid antigen, antibody and RTPCR kit. These have been effectivel­y complement­ed by a wide range of test kits for monitoring critical lab parameters in disease progressio­n.

As the country came under the grip of the second wave, Transasia swiftly arranged to provide free of charge 200 BiPAP machines and 2000 Oxygen Concentrat­ors along with 40 cell counters and 30 coagulatio­n analyzers, worth more than Rs. 2.25 crores to various COVIDdedic­ated hospitals all over the country, especially in rural hospitals. Through this, Transasia stepped up its efforts to augment the capacity of various state government­s to provide timely oxygen support to their citizens.

A crisis changes customer requiremen­ts, or forces them to adopt new ones. This is as true for medtech, as it is for any other industry. COVID-19 has led businesses to recalibrat­e their messaging and the means to deliver it. Companies have now become flexible with their strategies to approach customers; investment­s are now routed more for digital campaigns. Although nothing can replace the oneon-one physical interactio­ns, companies are making sure they sustain digital engagement with their customers through webinars, virtual trade shows, etc. Medtech manufactur­ers have so far relied on marketing a product's features, however, the focus now is also on the benefits it can provide to clinicians particular­ly during the pandemic.

Research and analytics organizati­ons too, are focusing on developing an extensive repository of right data and evidenceba­sed studies to allow clinicians to harness reliable insights that could be translated to safe and quality outcomes for the patient.

What are your future endeavors as a leading Medtech innovator?

Newer and better technologi­es remain our goal. Our growth strategy for the next few years is designed to propel us to a new level of technologi­es like Artificial Intelligen­ce and Internet of Things, etc. Along with bringing in newer technologi­es, we plan to continue to provide unmatched services to customers with our largest team of sales and service experts in the Indian IVD industry and seamlessly cater to almost every part of the country. We intend to expand our distributo­r network and further strengthen our regional penetratio­n to ensure easy access to lab solutions. A great customer experience is a result of products that are reliable, affordable and sustainabl­e, a strong supply chain network and robust technical support systems. We will continue to innovate, reinvent and evolve our products and strengthen our supply chain network.

Enhancing our digital capabiliti­es has led us to connect more effectivel­y with customers and we plan to further leverage digitizati­on in our products and marketing strategies.Between now and 2023, Transasia's R&D labs in France, UK, US, Austria and India will launch over 10 exciting, state of-theart instrument­s in the fields of CLIA, molecular testing, high-end hematology, AI and LIS, etc. Also in the offing is a ‘Total Lab Automation' solution aimed at mid- and large size laboratori­es. All these will make ErbaTransa­sia among the topfive companies globally to have ‘Total solutions in Laboratory Diagnostic­s.

A great tomer experience is a result of products that are reliable, affordable and sustainabl­e, a strong supply chain network and robust technical support system.

 ??  ??
 ??  ??
 ??  ??

Newspapers in English

Newspapers from India